From: Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
DAS28 at week 14
DAS28 at week 22
Specificity level
Cutoff
Sensitivity
PPV
NPV
0.90
5.47
0.36
0.34
5.55
0.41
0.95
5.97
0.35
0.51
6.10
0.37
0.56
0.91
0.98
6.40
0.32
6.85
0.16
0.62
0.89